ProstaLund AB (PLUN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProstaLund AB (PLUN) has a cash flow conversion efficiency ratio of -0.052x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.31 Million ≈ $-248.27K USD) by net assets (Skr44.54 Million ≈ $4.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PLUN market cap for the company's overall valuation and market capitalisation.
ProstaLund AB - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how ProstaLund AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ProstaLund AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProstaLund AB ranked by their cash flow conversion efficiency. Explore PLUN cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Strikewell Energy Corp
V:SKK
|
0.000x |
|
TTL Beteiligungs- und Grundbesitz-AG
F:TTO
|
0.226x |
|
Kollect on Demand Holding Ab
ST:KOLL
|
-0.012x |
|
ARCTIC BLUE BEVERAGES AB
F:U5L
|
0.143x |
|
Creo Medical Group PLC
LSE:CREO
|
-0.684x |
|
CERo Therapeutics Holdings, Inc. Common Stock
NASDAQ:CERO
|
0.076x |
|
Glen Eagle Resources Inc
V:GER
|
0.307x |
|
EUROPA MET. LTD POST CONS
F:WRE1
|
N/A |
Annual Cash Flow Conversion Efficiency for ProstaLund AB (2012–2024)
The table below shows the annual cash flow conversion efficiency of ProstaLund AB from 2012 to 2024. View PLUN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr55.18 Million ≈ $5.94 Million |
Skr-22.59 Million ≈ $-2.43 Million |
-0.409x | +4.89% |
| 2023-12-31 | Skr55.29 Million ≈ $5.95 Million |
Skr-23.80 Million ≈ $-2.56 Million |
-0.430x | -10.75% |
| 2022-12-31 | Skr41.69 Million ≈ $4.49 Million |
Skr-16.20 Million ≈ $-1.74 Million |
-0.389x | -137.43% |
| 2021-12-31 | Skr35.46 Million ≈ $3.82 Million |
Skr-5.80 Million ≈ $-624.60K |
-0.164x | +51.64% |
| 2020-12-31 | Skr25.35 Million ≈ $2.73 Million |
Skr-8.58 Million ≈ $-923.45K |
-0.338x | +17.44% |
| 2019-12-31 | Skr22.23 Million ≈ $2.39 Million |
Skr-9.12 Million ≈ $-980.92K |
-0.410x | +56.18% |
| 2018-12-31 | Skr12.71 Million ≈ $1.37 Million |
Skr-11.89 Million ≈ $-1.28 Million |
-0.936x | +20.02% |
| 2017-12-31 | Skr13.78 Million ≈ $1.48 Million |
Skr-16.11 Million ≈ $-1.73 Million |
-1.170x | -150.18% |
| 2016-12-31 | Skr30.81 Million ≈ $3.32 Million |
Skr-14.41 Million ≈ $-1.55 Million |
-0.468x | -11.23% |
| 2015-12-31 | Skr23.19 Million ≈ $2.50 Million |
Skr-9.75 Million ≈ $-1.05 Million |
-0.420x | +53.88% |
| 2014-12-31 | Skr11.89 Million ≈ $1.28 Million |
Skr-10.83 Million ≈ $-1.17 Million |
-0.911x | -23.12% |
| 2013-12-31 | Skr5.23 Million ≈ $563.26K |
Skr-3.88 Million ≈ $-417.01K |
-0.740x | -33.32% |
| 2012-12-31 | Skr4.69 Million ≈ $504.83K |
Skr-2.60 Million ≈ $-280.34K |
-0.555x | -- |
About ProstaLund AB
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow, a temporary prostate stent; Oruflow, a urine flow meter; and Schelin Catheter, a medical device intended for intraprostatic and periprostatic injection of legally mark… Read more